默克和MD安德森宣布免疫肿瘤实体肿瘤研究合作188bet体育网址
MD Anderson News Release August 13, 2015
Clinical trials to evaluate Merck’s KEYTRUDA® (pembrolizumab) in combination with other medicines and treatments across multiple tumor types
MD安德森新闻发布2015年8月13日
默克和The University of Texas MD Anderson Cancer Centerannounced a strategic clinical research collaboration to evaluate Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.
胃腺癌，胰腺癌和肝癌：根据协议的条款，合作研究，将在以下类型的肿瘤在3年期合作的开展。第一个研究计划于今年晚些时候开始招生。
该协议旨在确定什么样的组合模式将通过探索有前途的新的替代工作最好与KEYTRUDA在这些类型的肿瘤。这些研究将并行进行，以确定在可能的最有效的方式最佳方案。所有的研究都将有国家的最先进的监控协议和内置的灵活性，以充分利用现有的最新信息优势。
“Through these types of collaborations, we are able to engage in larger, more comprehensive studies that aim to accelerate the pace of discovery,” said帕特里克HWU，医学博士, division head,Cancer Medicine在MD安德森。“我们相信，这一新协议将有助于新的癌症治疗方法，我们期望的患者，值得交货速度。”
“This agreement embodies Merck’s commitment to collaborating with leaders in the field to rapidly advance breakthrough science and further the goal of bringing new treatment approaches to patients,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “Agreements like this are an integral part of our strategy to evaluate KEYTRUDA in multiple tumors and combinations.”
MD Anderson been instrumental in researching breakthrough cancer therapies, and was a key contributor to early investigations exploring the use of KEYTRUDA in the treatment of multiple tumor types. Past research collaborations with Merck and MD Anderson were pivotal in achieving the FDA approval of KEYTRUDA as a treatment for unresectable or metastatic melanoma.
KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By binding to the PD-1 receptor and blocking the interaction with the receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
KEYTRUDA is indicated in the United States at a dose of 2 mg/kg administered as an intravenous infusion over 30 minutes every three weeks for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
Merck is advancing a broad and fast-growing clinical development program for KEYTRUDA with more than 100 clinical trials – across more than 30 tumor types and enrolling more than 16,000 patients – both as a monotherapy and in combination with other therapies.